frontiers | Frontiers in Medical Technology

TYPE Correction
PUBLISHED 16 January 2026
DOI 10.3389/fmedt.2025.1756558

OPEN ACCESS

EDITED AND REVIEWED BY
Ahmed Esmat Abdel Moneim,
Helwan University, Egypt

*CORRESPONDENCE
Salma Ajraoui
✉ salma.ajraoui@iqvia.com

RECEIVED 28 November 2025
ACCEPTED 04 December 2025
PUBLISHED 16 January 2026

CITATION
Ballester BR, Reaney M, Mack C and Ajraoui S (2026) Correction: A hybrid, iterative approach, to support the development of fit-for-purpose sensor-derived measures.
Front. Med. Technol. 7:1756558.
doi: 10.3389/fmedt.2025.1756558

Correction: A hybrid, iterative approach, to support the development of fit-for-purpose sensor-derived measures

Belen R. Ballester[1], Matthew Reaney[2], Christina Mack[3] and Salma Ajraoui[2]*

[1]Patient Centered Solutions, IQVIA Inc., Barcelona, Spain, [2]Patient Centered Solutions, IQVIA Inc., London, United Kingdom, [3]IQVIA Inc., Durham, NC, United States

KEYWORDS

DHT, digital measures, fit-for-purpose DHTs, patient-centricity, sensor-derived COAs

A Correction on
A hybrid, iterative approach, to support the development of fit-for-purpose sensor-derived measures

By Ballester BR, Reaney M, Mack C and Ajraoui S (2025). Front. Med. Technol. 7:1567537. doi: 10.3389/fmedt.2025.1567537

Error in figure/table

Wrong content

There was a mistake in Figures 3, 4 as published. During publication the same figure was added twice instead of the right figure. The corrected Figures 3, 4 appears below.


What to measure
Identify MAH from patients and HCPs (1° & 2° research)
e.g., ability to perform ambulatory activities
Derive COIs (1° & 2° research)
e.g., walking capacity
Iterative Process
How to feasibly measure
Derive outcome measures
e.g., ability to perform ambulatory activities
Identification of DHTs to collect the selected measures
Appraisal of feasibility, verification and usability to refine DHT and measures selection
e.g., walking capacity
Debrief shortlisted measure with patients and HCPs
How to reliably measure
Define root endpoint
e.g., % change from baseline in step counts compared to placebo at week 4
Determine psychometric support for potential measures, including (importantly) sensitivity to change (clinical validation)
Ascertain relevance/clarity/understandability of derived measures to patients and HCPs
What is the outcome measure
Is the measure meaningful to patients
Yes
No
Endpoint
Is the measure meaningful to HCPs
Yes
No
Biomarker
Yes, and same biological mechanisms as true endpoint and advantageous psychometrics
Surrogate Endpoint
No Endpoint

FIGURE 3



FIGURE 4

Figure 3 should be as per below (which is current Figure 4 in the published article):

Figure 4 should be as per below:

The original version of this article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.